Bixiye
QP33-19 SmartChoice Program for Fully Insured Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Natiijooyinka Raadinta
Soo bandhiga 2731 - 2740 ee natiijooyinka 4130
Bixiye
QP32-19 Pharmacy Benefit Exclusion for Glyrx-PF, Libtayo, Lumoxiti, Onpattro, Poteligeo, and Xerava
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP34-19 Pharmacy Benefit Exclusion for Antineoplastic and Adjunctive Therapies
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP31-19 Change to Outpatient Therapies Prior Authorization Requirements for Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP29-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Arikayce
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP23-19 Reminder Payment Policy Auditing System
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP28-19 Interest Paid on Clean Claims
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP24-19 New Behavioral Health Coding for Early Intensive Behavioral Intervention (EIBI) Services for Commercial Lines of Business
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP27-19 Medicare Hospice reminder for Medicare Advantage Members
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP25-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Gonadotropin Hormones
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019